title: Molecular profiling is not the future: it is now!
abstract: Bobby Reddy speaks to Gemma Westcott, Commissioning Editor: Dr Reddy graduated from the UCLA School of Medicine in 1996. Shortly after, he obtained an internship and did his residency in Internal Medicine at Harbor UCLA Medical Center. He then went on to do his fellowship in Hematology and Oncology at City of Hope. Since then, he has been working in private practice (full and part time) for the past 11 years and has had an academic appointment as teaching faculty at Harbor UCLA. Prior to his current role, Dr Reddy worked as a senior medical director as Caris Life Sciences.
authors.affiliation: Caris Life Sciences, 6655 N MacArthur Blvd, Irving, TX 75039, USA.
authors.forename: Bobby
authors.initials: B
authors.lastname: Reddy
authors.forename: Gemma
authors.initials: G
authors.lastname: Westcott
mesh_terms: D020869:Gene Expression Profiling; D006801:Humans; D009369:Neoplasms / Q000235:genetics*
keywords: Caris Life Sciences; PD-1; PD-L1; SABCS; San Antonio Breast Cancer Symposium; cancer biomarkers; cancer research; luminal breast cancer; male breast cancer; molecular profiling; personalized medicine; precision medicine; triple-negative breast cancer; tumor profiling